Results 171 to 180 of about 2,837,491 (342)
STUDY XXIII. THE RELATION BETWEEN AMYLASE RETENTION AND EXCRETION AND NON-PROTEIN NITROGEN RETENTION IN EXPERIMENTAL URANIUM NEPHRITIS [PDF]
Reginald Fitz
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source
How The Timing of Grade Retention Affects Outcomes: Identification and Estimation of Time-Varying Treatment Effects [PDF]
Increasingly, grade retention is viewed as an important alternative to social promotion, yet evidence to date is unable to disentangle how the effect of grade retention varies by abilities and over time.
Jane Cooley Fruehwirth +2 more
core
EFFECT OF BILIARY FISTULA ON BROMSULPHALEIN RETENTION, SERUM PHOSPHATASE, AND BILE PHOSPHATASE [PDF]
Victor A. Drill +3 more
openalex +1 more source
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
A FURTHER STUDY OF NITROGEN RETENTION IN THE BLOOD IN EXPERIMENTAL ACUTE NEPHRITIS [PDF]
Howard T. Karsner, W. Denis
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source

